An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

Abstract

The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months. The study was carried out on 234 patients who received THAL for relapsed/refractory myeloma. Out of the 234 patients, 129 patients (55.1%) responded to THAL with a mean response duration of 11.9 months (ranging from 1 to 48) and an overall survival rate of 20.3 months (ranging 1-55 months). In 64 patients (27.4% of the whole group), the response to THAL lasted ≥ 18 months with a mean response lasting 24 months. Statistical analysis of the group of nonresponders and patients with long-term response to THAL showed a significantly higher serum albumin level (P = 0.0003) and haemoglobin level (P = 0.05), as well as a lower β2 microglobulin (β2M) (P = 0.022), LDH (P = 0.045) serum level in patients with long-term response. In this study, the LDH and serum albumin level were predictors for response to THAL therapy. The β2M serum level was not a predictor for response to THAL The albumin serum level was the best parameter distinguishing the group of patients with long-term response to THAL from the entire responding group (P = 0.02). © 2004 Cancer Research UK.